Allbirds, Inc. (BIRD)
NASDAQ: BIRD · Real-Time Price · USD
9.50
-0.58 (-5.75%)
Aug 1, 2025, 4:00 PM - Market closed
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $9.50, which forecasts no change in the stock price over the next year. The lowest target is $5.00 and the highest is $14.
Price Target: $9.50 (0.00%)
Analyst Consensus: Buy
* Price targets were last updated on May 12, 2025.
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | -47.37% | May 12, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +47.37% | Apr 11, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $12 → $8 | Hold | Maintains | $12 → $8 | -15.79% | Jan 21, 2025 |
| Wedbush | Wedbush | Hold Maintains $18 → $14 | Hold | Maintains | $18 → $14 | +47.37% | May 9, 2024 |
| Wedbush | Wedbush | Hold Maintains $20 → $18 | Hold | Maintains | $20 → $18 | +89.47% | Mar 13, 2024 |
Financial Forecast
Revenue This Year
179.13M
from 189.76M
Decreased by -5.60%
Revenue Next Year
188.37M
from 179.13M
Increased by 5.16%
EPS This Year
-9.84
from -11.87
EPS Next Year
-7.93
from -9.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 190.0M | 196.4M | 205.1M |
| Avg | 179.1M | 188.4M | 199.3M |
| Low | 169.1M | 178.3M | 191.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.1% | 9.6% | 8.9% |
| Avg | -5.6% | 5.2% | 5.8% |
| Low | -10.9% | -0.5% | 1.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -9.61 | -6.96 | -4.18 |
| Avg | -9.84 | -7.93 | -4.06 |
| Low | -10.37 | -9.29 | -3.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.